These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35615295)

  • 1. Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success.
    Morrisette T; Molina KC; Da Silva B; Mueller SW; Damioli L; Krsak M; Miller MA; Fish DN
    Open Forum Infect Dis; 2022 Jun; 9(6):ofac028. PubMed ID: 35615295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Tolerability of More than Six Days of Tedizolid Treatment.
    Mensa Vendrell M; Tasias Pitarch M; Salavert Lletí M; Calabuig Muñoz E; Morata Ruiz L; Castells Lao G; López Suñé E; Mensa Pueyo J; Oltra Sempere MR; Pedro-Botet Montoya ML; Isernia V; Reynaga Sosa EA; Moreno Nuñez L; Pasquau Liaño J; Sequera Arquelladas S; Yuste Ara JR; Soriano Viladomiu A
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32312777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction of thrombocytopenia caused by linezolid with scheduled sequential tedizolid use in patients with vertebral osteomyelitis by antibiotic resistant Gram-positive organisms.
    Ueda T; Nakajima K; Ichiki K; Ishikawa K; Yamada K; Tsuchida T; Otani N; Takahashi Y; Ishihara M; Takubo S; Iijima K; Ikeuchi H; Uchino M; Kimura T; Takesue Y
    J Infect Chemother; 2022 Jul; 28(7):1023-1028. PubMed ID: 35477667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-Life Evidence for Tedizolid Phosphate in the Treatment of Cellulitis and Wound Infections: A Case Series.
    Shlyapnikov S; Jauregui A; Khachatryan NN; Kurup A; de la Cabada-Bauche J; Leong HN; Li L; Wilcox MH
    Infect Dis Ther; 2018 Sep; 7(3):387-399. PubMed ID: 30003513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects.
    Kim Y; Kim A; Lee S; Choi SH; Lee DY; Song JS; Lee H; Jang IJ; Yu KS
    Clin Ther; 2017 Sep; 39(9):1849-1857. PubMed ID: 28865799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid.
    Flanagan S; Fang E; Muñoz KA; Minassian SL; Prokocimer PG
    Pharmacotherapy; 2014 Sep; 34(9):891-900. PubMed ID: 24989138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.
    Prokocimer P; Bien P; Deanda C; Pillar CM; Bartizal K
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4608-13. PubMed ID: 22687509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tedizolid Phosphate: a Next-Generation Oxazolidinone.
    Rybak JM; Roberts K
    Infect Dis Ther; 2015 Feb; 4(1):1-14. PubMed ID: 25708156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan - Results of a randomised, multicentre phase 3 study.
    Mikamo H; Takesue Y; Iwamoto Y; Tanigawa T; Kato M; Tanimura Y; Kohno S
    J Infect Chemother; 2018 Jun; 24(6):434-442. PubMed ID: 29530544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, Safety and Tolerability of Single Oral or Intravenous Administration of 200 mg Tedizolid Phosphate in Adolescents.
    Bradley JS; Flanagan SD; Arrieta AC; Jacobs R; Capparelli E; Prokocimer P
    Pediatr Infect Dis J; 2016 Jun; 35(6):628-33. PubMed ID: 26910588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: Subgroup analysis of 2 randomized phase 3 trials.
    De Anda C; Anuskiewicz S; Prokocimer P; Vazquez J
    Medicine (Baltimore); 2017 Dec; 96(52):e9163. PubMed ID: 29384903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
    Wunderink RG; Roquilly A; Croce M; Rodriguez Gonzalez D; Fujimi S; Butterton JR; Broyde N; Popejoy MW; Kim JY; De Anda C
    Clin Infect Dis; 2021 Aug; 73(3):e710-e718. PubMed ID: 33720350
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Brown-Elliott BA; Wallace RJ
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.
    Moran GJ; Fang E; Corey GR; Das AF; De Anda C; Prokocimer P
    Lancet Infect Dis; 2014 Aug; 14(8):696-705. PubMed ID: 24909499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.
    Shorr AF; Lodise TP; Corey GR; De Anda C; Fang E; Das AF; Prokocimer P
    Antimicrob Agents Chemother; 2015 Feb; 59(2):864-71. PubMed ID: 25421472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone.
    Zurenko G; Bien P; Bensaci M; Patel HN; Thorne G
    Ann Clin Microbiol Antimicrob; 2014 Sep; 13():46. PubMed ID: 25238753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.
    Lv X; Alder J; Li L; O'Riordan W; Rybak MJ; Ye H; Zhang R; Zhang Z; Zhu X; Wilcox MH
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of tedizolid and comparator agents against Gram-positive pathogens responsible for bone and joint infections.
    Ract P; Piau-Couapel C; Compain F; Auzou M; Michon J; Cattoir V
    J Med Microbiol; 2017 Oct; 66(10):1374-1378. PubMed ID: 28920854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid.
    Mikamo H; Nagashima M; Kusachi S; Fujimi S; Oshima N; De Anda C; Takase A
    J Infect Chemother; 2022 Sep; 28(9):1235-1241. PubMed ID: 35718656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.